Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

By Michael Michael   Gibbs Peter   Smith Robert   Godwood Alex   Oliver Stuart   Tebbutt Niall  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 253-261

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John   McCall Shannon   Nixon Andrew   Brady John   Pang Herbert   Rushing Christel   Cohn Allen   Starodub Alexander   Arrowood Christy   Haley Sherri   Meadows Kellen   Morse Michael   Uronis Hope   Blobe Gerard   Hsu S.   Zafar S.   Hurwitz Herbert  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 330-339

Springer Publishing Company

Access to resources Recommend Favorite

Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer: Results of Phase I and II Studies

By Yuuki Satoshi  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 243-249

Adis International

Access to resources Recommend Favorite

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

By Boku Narikazu   Muro Kei   Machida Nozomu   Hashigaki Satoshi   Kimura Nobuyuki   Suzuki Mie   Lechuga Mariajose   Miyata Yoshinori  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 261-270

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1501-1510

Springer Publishing Company

Access to resources Recommend Favorite